MiNK Therapeutics, Inc. (INKT) Stock

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company based in New York, New York, specializes in the discovery, development, and commercialization of innovative allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies. Formerly known as AgenTus Therapeutics, Inc., the company rebranded to MiNK Therapeutics, Inc. in its pursuit of pioneering treatments for cancer and immune-mediated diseases. MiNK Therapeutics is at the forefront of advancing AGENT-797, its lead product candidate in Phase 1 clinical trials.

AGENT-797 represents a promising off-the-shelf, allogeneic iNKT cell therapy designed to address various forms of myeloma. This innovative therapy underscores MiNK Therapeutics' commitment to leveraging cutting-edge biopharmaceutical technologies to improve patient outcomes in oncology and beyond. With a strong emphasis on scientific rigor and therapeutic innovation, MiNK Therapeutics aims to redefine treatment standards in the field of immune-mediated diseases.

Founded in 2017 and operating as a subsidiary of Agenus Inc., MiNK Therapeutics benefits from strategic collaborations and a robust research framework. The company continues to expand its pipeline and explore novel applications of iNKT cell therapies, positioning itself as a leader in the rapidly evolving landscape of biopharmaceutical innovation.